C5 and paroxysmal nocturnal hemoglobinuria: This in vitro study helps in understanding what happens in vivo in PNH patients on eculizumab and it paves the way for alternative strategies to overcome the clinical consequences of C3 binding in PNH patients who already benefit, completely or partially, from C5 blockade [34, 57].